A) Submitted by: Portable Therapeutix
4254 Bluebonnet Dr
Stafford, TX 77477
1-617-331-7524

Contact: Sharyn Orton, Ph.D.
MEDicept, Inc.
200 Homer Ave
Ashland, MA 01721
401-330-8264

Date prepared: January 31, 2014

B) Classification Name: Massager, Powered Inflatable Tube – Product code IRP
Pack, Cold, Reusable – Product code IME

Common Name: Powered inflatable tube massager
Cold Pack

Proprietary Name: Portable Therapeutix Squid Active Cold Compression device
and Cold Pack for OTC Use

Device Regulations: 21 CFR 890.5650, Class II
and Class 21 CFR 890.5700, Class I 510(k) exempt

Product Codes: IRP; IME

C) Predicates: K123829 Portable Therapeutix Squid Active Cold
Compression Cold Pack

D) Device Description:

The Squid Active Cold Compression device and Cold Pack for OTC Use combines
intermittent compression with cold therapy. The Squid simulates kneading and stroking
of tissues using an inflatable garment attached to a gel ice pack and connected to a pre-
programmed air pump. The Squid may be used for the leg, foot, feet, arm, shoulders,
lower back, and hands.
The device is manufactured with the following components:

1. A portable external pump-controller unit containing the pneumatic compressor (air pump) that may be run on AC-DC external power supply or a built-in lithium battery.

2. A wrap that contains an air bladder with sequential compression capability and Velcro attachments for the cold pack. The wrap connects to the pump controller via a flexible tube. There may also be an accessory piece to the wrap to provide an additional securing mechanism. Wraps come in two configurations and three sizes.

3. Reusable thermogel cold pack

The Squid Active Cold Compression device and Cold Pack was cleared for marketing as a prescription use device in K123829. The Squid Active Cold Compression device and Cold Pack described in this 510(k) Summary will be marketed as an over-the-counter (OTC) use device.

E) Intended Use/Indication for Use:

The Squid Active Cold Compression device and Cold Pack for OTC use is indicated for the temporary relief of minor muscle aches and pains.

The compression device is indicated for temporary increase in circulation of the treated areas in people who are in good health, and simulates kneading and stroking of tissues using an inflatable garment.

The cold pack is indicated for localized therapy in situations where cold temperature therapy is necessary or desirable.

F) Comparison to Predicate Device(s):

The Portable Therapeutix Squid Active Cold Compression device and Cold Pack for OTC use is the same device as K123829. There were no changes to the K123829 device.
## Portable Therapeutix Squid

### Active Cold Compression device and Cold Pack for OTC Use

<table>
<thead>
<tr>
<th>Product code</th>
<th>IRP; IME</th>
<th>IRP; IME</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Indication for Use</strong></td>
<td>The Squid Active Cold Compression device and Cold Pack for OTC use is indicated for the temporary relief of minor muscle aches and pains.</td>
<td>The Squid Active Cold Compression device and Cold Pack is indicated for the temporary relief of minor muscle aches and pains.</td>
</tr>
<tr>
<td></td>
<td>The compression device is indicated for temporary increase in circulation of the treated areas in people who are in good health, and simulates kneading and stroking of tissues using an inflatable garment.</td>
<td>The compression device is indicated for temporary increase in circulation of the treated areas in people who are in good health, and simulates kneading and stroking of tissues using an inflatable garment.</td>
</tr>
<tr>
<td></td>
<td>The cold pack is indicated for localized therapy in situations where cold temperature therapy is necessary or desirable.</td>
<td>The cold pack is indicated for localized therapy in situations where a physician determines that cold temperature therapy is necessary or desirable.</td>
</tr>
</tbody>
</table>

| **Target** | Leg, foot, arm, shoulders, lower back, hands |
| **OTC use** | Yes | No |

---

**Portable Therapeutix OTC Squid**

**Traditional 510(k) Premarket Notification**
### Principle of Intermittent Compression

#### Operation / Mechanical characteristics

<table>
<thead>
<tr>
<th>Intensity Settings (Modes)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 - 30 mm Hg</td>
</tr>
<tr>
<td>2 - 50 mm Hg</td>
</tr>
<tr>
<td>3 - 70 mm Hg</td>
</tr>
<tr>
<td>4 - 85 mm Hg</td>
</tr>
</tbody>
</table>

#### Pressure range

<table>
<thead>
<tr>
<th>Range</th>
</tr>
</thead>
<tbody>
<tr>
<td>0 - 85 mm Hg</td>
</tr>
</tbody>
</table>

#### Total treatment time

15 minutes

#### Pressure control

Microprocessor and pressure sensor

#### Inflation by

Pressurization pump

#### Deflation by

Exhaust valve

#### Power source

120V 60 Hz, consumption 26W; AC adapter: 120V 60 Hz, consumption 36W; Lithium battery

#### Cold Pack

Yes

---

### Substantial Equivalence Discussion

The Portable Therapeutix Squid Cold Compression System for OTC use is the same device as the FDA cleared Squid. Treatment targets, total treatment time and mechanical intermittent compression are the same. There is no change to the software, materials used, or power source. There is the addition of alignment markers on the wraps and gel pack to assist in the aligning the wrap with the gel pack for Velcro attachment.

The Portable Therapeutix Squid Cold Compression System has the same indications for use as the predicate device, with the addition of OTC use.

### Performance Testing

There were no changes to the K123829 device. The following were described or testing successfully performed and reported in FDA cleared K123829:

- Biocompatibility
- Electrical Safety/EMC (including batteries)
- Bench testing including the following tests: Baseline Verification; Compression Bladder Leak Verification Test; Blow out Valve Test; Gel Pack Seal Leak Test; Low Pressure Verification Test; Max Pressure, -Total Time, -Max Compression Time, -

---

Portable Therapeutix OTC Squid | Traditional 510(k) Premarket Notification | 6-4
Min Compression Time, -Max Deflation Time, -Min Deflation Time, -Pressure
Gauge Data; Solenoid Valve Release Test (High pressure release)

- Shelf life of batteries and gel pack
- Reprocessing/sterilization - the device is reusable and not supplied sterile.
  Cleaning instructions are included in the Instructions for Use.

For this application (K133483) a summative Usability Study was successfully conducted
on representative users for OTC use. Findings from the study served to validate that the
Squid - Active Cold Compression device and Cold Pack is usable by the devices’
tended users.

Conformity to Standards

There is no change in conformance standards from K123829. The Squid complies with:

  General Requirements for Safety, 1988; Amendment 1, 1991-11, Amendment 2,
  1995).
  requirements for basic safety and essential performance – Collateral standard:
  Electromagnetic compatibility – Requirements and Tests

Conclusion

The Portable Therapeutix Squid Cold Compression System device and Cold Pack for
OTC use is substantially equivalent to the predicate device.
March 11, 2014

Portable Therapeutix, LLC
c/o MEDcept, Inc.
Attn: Sharyn Orton Ph.D., Senior Consultant
200 Homer Avenue
Ashland, MA 01721

Re: K133483
Trade Name: Portable Therapeutix Squid Active Cold Compression Device and Cold Pack for OTC use
Regulation Number: 21 CFR 890.5650
Regulation Name: Powered inflatable tube massager
Regulatory Class: Class II
Product Code: IRP, IME
Dated: February 5, 2014
Received: February 7, 2014

Dear Dr. Orton:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA).

You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA’s issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act’s requirements, including, but not limited to: registration and listing (21
CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH’s Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,

Carlos L. Peña -S

Carlos L. Peña, PhD, MS
Director
Division of Neurological and Physical Medicine Devices
Office of Device Evaluation
Center for Devices and Radiological Health

Enclosure
Indications for Use

The Squid Active Cold Compression device and Cold Pack for OTC use is indicated for the temporary relief of minor muscle aches and pains.

The compression device is indicated for temporary increase in circulation of the treated areas in people who are in good health, and simulates kneading and stroking of tissues using an inflatable garment.

The cold pack is indicated for localized therapy in situations where cold temperature therapy is necessary or desirable.

Type of Use (Select one or both, as applicable)

- [ ] Prescription Use (Part 21 CFR 801 Subpart D)
- [x] Over-The-Counter Use (21 CFR 801 Subpart C)

For FDA use only

Concurrence of Center for Devices and Radiological Health (CDRH) (Signature)

Carlos L. Pena -S
This section applies only to requirements of the Paperwork Reduction Act of 1995.

*DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.*

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services
Food and Drug Administration
Office of Chief Information Officer
Paperwork Reduction Act (PRA) Staff
PRAStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."